2026-10-25
LifeStance Health Group, clears the business-activity screen and the figures we can measure look clean, but one or more financial figures are still pending, so the verdict is not final yet.
NAS100 28,385 −3.46%
S&P 7,580 −1.82%
GOLD $3,899 −3.29%
BTC $77,887 +0.58%
VIX 19.42 +12.91%
latest tape · as of 16:00 UTC
The Screen · Healthcare · Medical Care Facilities
LifeStance Health Group, Inc.
LFST · Nasdaq · USD · Market cap $4.7B · 8,349 employees
LifeStance Health Group, Inc., through its subsidiaries, provides outpatient mental health services to children, adolescents, adults, and geriatrics in the United States.
Not yet scored13.40 USD
Price as of 30 Oct 2026Daily close, not a live quote
Screened 2026-10-30 · the tape above runs as of 16:00 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
- Price13.40 USD at the 30 Oct 2026 close
- Ethical screenNot yet scored
- OptionsOpen interest leans heavily to calls (put/call 0.29)
- Last reviewed30 Oct 2026 (2 days ago)
- Release timesRelease and earnings times on your chart: Event Guard Mentor
A summary of the dated readings below, not a live quote and not advice.
PRICE · ONE YEAR
Our fair-value range: $10.80 to $14.07, base estimate $12.24 (screen dated 2026-10-30).
- Trend Accumulation
- Insiders no filings inside 60 days, left as found
- Positioning no disclosures inside 60 days, left as found
- Options put/call open interest 0.29, read 2026-11-01
- Ethical screen not yet scored
Price13.40 USD
Fair value12.24
Ethical score70.0/100
Our investment reviews on this name
2026-10-28Read Accumulation12.33+8.7% to today ✓Markdown gives way to Accumulation with volume flow in agreement
2026-10-02Read Markdown12.67+5.8% to today Markup gives way to Markdown after a 49% rise in 13 weeks
2026-07-02Read Markup8.50+57.6% to today ✓First review on file: Markup
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
The full research record, in depth, below
This name holds its accumulation label.
LifeStance Health Group, Inc. holds its Accumulation at $13.40. The statistical read favours the buyers, held for 101 days.
| Phase | Accumulation |
| Quantitative state | The statistical read favours the buyers, held for 101 days |
| Price at the screen | $13.40 |
| Valuation | 94.85 trailing · 28.62 forward price to earnings |
| Values screen | Not scored · score 70.0 |
| Beta | 1.24 |
Five Screens, Shown in Full
This security has not been fully scored against the values screen yet.
| Test | Figure | Limit | What it means | Status |
|---|---|---|---|---|
| Business activity | Permissible | Core business clean | Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending. | Pass |
| Debt load | 21.53% | Below 33% | Interest-bearing debt is just 21.5% of its assets, well under the one-third ceiling: it does not run on borrowed money. | Pass |
| Interest-bearing cash | 0.00% | Below 33% | Cash held in interest-bearing accounts and securities is 0.0% of assets, under the one-third limit. | Pass |
| Receivables | 15.62% | Below 49% | Money owed to the company is 15.6% of assets, under the 49% limit. | Pass |
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical ReadThe Read, in Plain English
LifeStance Health Group, clears the business-activity screen and the figures we can measure look clean, but one or more financial figures are still pending, so the verdict is not final yet.
Read as at 2026-10-31. It updates when the underlying figures move, and past reads are kept below.
2026-09-24
Clears
LifeStance Health Group, clears all five screens. Its business is in a permissible area, its interest-bearing debt is about 22%, inside the ~33% line, and almost none of its income is interest, so it passes.
Earlier reads, kept as written. The ethical profile is tracked over time, not overwritten.
What the Numbers Say It Is WorthThe Fair Value Range
How a fair value is estimated: discounted cash flow (DCF).
Fair value range in USD, drawn from the 2026-10-30 screen. The gold marker is the market price at the same screen. The price runs 8.7% above the base estimate.
Third-party analyst targets: 10 covering, consensus Buy. The average target sits +12% from the screen price.
Reading the gap · Our more conservative model reads it as fully-to-richly valued here, while the Street is more bullish: a quality-at-a-fair-price name rather than a deep-value one.
Price History & ProjectionsWhere our models see it going: fair-value estimate $12.24, with a range of $10.80 to $14.07, dated to the 2026-10-30 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain WordsTherapy demand climbs but the price tag does not
Every time a parent books an appointment for an anxious child or a worker seeks help after burnout, LifeStance routes them through its network of outpatient clinics. Revenue is rising 21% a year on broader access to mental health care across ages. The model bundles evaluations and therapy under one roof, yet the business still converts only 2% of sales into profit and posts a 2% return on equity.
The shares sit at $11.58 against a fair value of $10.06, leaving a negative margin of safety and a forward multiple of 29.5 times earnings. Analysts carry a buy consensus with a $12 median target, yet the opportunity rating remains none because growth has not translated into durable cash returns or visible competitive advantage.
Risks sit around thin margins that leave little buffer if reimbursement rates tighten or clinician costs rise. The ethical screen clears, but the valuation offers scant protection against execution shortfalls in a crowded field. Analysis, not advice.
| Forward P/E | 28.6xfairly priced for its growth rate |
| Trailing P/E | 94.8xexpensive: the price assumes strong growth ahead |
| EPS, trailing | 0.13 |
| EPS, forward | 0.43 |
| Revenue growth | +26.1%strong top-line growth |
| Profit margin | 3.2%barely profitable |
| Return on equity | 3.4%a modest return on shareholder capital |
| FCF yield | 3.68% |
| Debt to equity | 0.32minimal debt: a conservative balance sheet |
| Current ratio | 1.38adequate liquidity, worth monitoring |
| Beta | 1.24moves a little more than the market |
| Short interest, float | 0.08% |
| 52-week range | 4.77 - 13.56 |
| Market cap | $4.7B |
| Employees | 8,349 |
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The main risks here are ordinary market swings and the chance our fair-value read proves too optimistic.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to TradeLFST trades on Nasdaq. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
Every Entry, As Written
2026-11-01
Accumulation $13.40
+3.6% Entry 13
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 3.6% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it A. Technically it is holding around 41% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 37%. Our forward projection puts the odds of a 10% gain over the next month near 29%. The street (9 analysts) rates it none, with a mean price target of $11. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-31
Accumulation $12.93
+0.0% Entry 12
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it A. Technically it is holding around 41% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 37%. Our forward projection puts the odds of a 10% gain over the next month near 29%. The street (9 analysts) rates it none, with a mean price target of $11. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-30
Accumulation $12.93
+0.0% Entry 11
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it A. Technically it is holding around 41% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 37%. Our forward projection puts the odds of a 10% gain over the next month near 29%. The street (9 analysts) rates it none, with a mean price target of $11. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-29
Accumulation $12.93
+4.9% Entry 10
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 4.9% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it A. Technically it is holding around 41% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 37%. Our forward projection puts the odds of a 10% gain over the next month near 29%. The street (9 analysts) rates it none, with a mean price target of $11. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-28
Accumulation · changed $12.33
-0.3% Entry 9
The framework has shifted from markdown to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.3% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it A. Technically it is holding around 41% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 37%. Our forward projection puts the odds of a 10% gain over the next month near 29%. The street (9 analysts) rates it none, with a mean price target of $11. Insiders have been net sellers over the past quarter.
2026-10-21
Markdown $12.37
-0.4% Entry 8
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.4% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 30% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 37%. Our forward projection puts the odds of a 10% gain over the next month near 29%. The street (9 analysts) rates it none, with a mean price target of $11. Insiders have been net sellers over the past quarter.
2026-10-14
Markdown $12.42
-2.0% Entry 7
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 2.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 21% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 37%. Our forward projection puts the odds of a 10% gain over the next month near 29%. The street (9 analysts) rates it none, with a mean price target of $11. Insiders have been net sellers over the past quarter.
2026-10-02
Markdown · changed $12.67
+4.3% Entry 6
The framework has shifted from markup to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 4.3% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 21% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 37%. Our forward projection puts the odds of a 10% gain over the next month near 29%. The street (9 analysts) rates it none, with a mean price target of $11. Insiders have been net sellers over the past quarter.
2026-09-04
Markup $12.15
+4.9% Entry 5
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 4.9% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 21% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 37%. Our forward projection puts the odds of a 10% gain over the next month near 29%. The street (9 analysts) rates it none, with a mean price target of $11. Insiders have been net sellers over the past quarter.
2026-08-04
Markup $11.58
+36.2% Entry 4
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 36.2% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 21% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 37%. Our forward projection puts the odds of a 10% gain over the next month near 29%. The street (9 analysts) rates it none, with a mean price target of $11.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
- /C O R R E C T I O N - LifeStance Health/ Yahoo Finance · 3d ago
- Teladoc Soars 11% on Q3 Beat and Raised Outlook as “Insurance Revenue Exceeded Our Expectations” Yahoo Finance · 3d ago
- Is LifeStance Health Group (LFST) A Bargain on Cash Flow? Yahoo Finance · 6d ago
- 3 Small-Cap Stocks We Think Twice About Yahoo Finance · 12d ago
- LifeStance to Host Third Quarter 2026 Earnings Conference Call on November 5, 2026 Yahoo Finance · 17d ago
Headlines from third-party outlets, linked for reference: not our reporting, not advice.
OPCHOption Care Health, Inc.
CONConcentra Group Holdings Parent, Inc.
NHCNational HealthCare Corporation
CHEChemed Corporation
ACHCAcadia Healthcare Company, Inc.
PACSPACS Group, Inc.
Screened names in the same industry · explore each on its own page.
| Date | Insider | Title | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-13 | Deluca Teresa | Dir | S - Sale | 20,441 | $249,993 |
Public filings, recorded as found. The full tape lives at Insider Intelligence.
| Period | Price then | Price return | Divs per share | $1,000 became | Total return |
|---|---|---|---|---|---|
| 1 month | $7.67 | +1.9% | · | $1,019 | +1.9% |
| 2 months | $6.40 | +22.1% | · | $1,221 | +22.1% |
| 3 months | $6.33 | +23.5% | · | $1,235 | +23.5% |
| 6 months | $6.76 | +15.6% | · | $1,156 | +15.6% |
| 1 year | $5.72 | +36.6% | · | $1,366 | +36.6% |
| 2 years | $5.35 | +46.1% | · | $1,461 | +46.1% |
| 3 years | $8.50 | -8.1% | · | $919 | -8.1% |
| 5 years | $24.00 | -67.4% | · | $326 | -67.4% |
Historical returns from market close data. Past performance does not guarantee future results.
This entry now belongs to the ledger. Whatever LFST does next, these words stay.
Membership
Thirteen thousand names carry this page. One desk keeps them honest.
Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.
Join the deskScreening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.